Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

Shaji Kumar MD, Sundar Jagannath, Katja C. Weisel MD, Laura Rosiñol Dachs, Meletios-Athanasios Dimopoulos, David S. Siegel MD PhD, Jorge Monge MD, Xavier Leleu, Juan Du, Javier de la Rubia, Jae Hoon Lee, María-Victoria Mateos, Borja Puertas Martínez, Alessandro Gozzetti, Dominik Dytfeld, Enrique M. Ocio, Joan Bladé MD PhD, Shuji Ozaki, Meral Beksac MD, Fernando Escalante, Brian G.M. Durie